Allergan Plc (AGN) 254.32 $AGN Allergan plc Completes

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allergan Plc (AGN) 254.32 $AGN

Allergan plc Completes Divestiture of Global Generics Business to Teva Pharmaceuticals
PR Newswire - 29 mins ago
Allergan plc (NYSE: AGN) today announced that it has completed the divestiture of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd. Allergan has received $33.4 billion in cash and 100.3 million shares of Teva stock valued at $5.4 billion based on the opening price of $53.39 for Teva Pharmaceutical Industries Ltd. shares on August 2, 2016. These shares are subject to a twelve month holding period post-close of the transaction.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)

California Life Sciences Association Announces Expansion of Board of Directors
BusinessWire - Tue Aug 02, 7:00AM CDT
California Life Sciences Association (CLSA) today announced an expansion of its board of directors, adding two new members. Alex Kelly, Executive Vice President, Chief Communications Officer, Allergan and Jens H. Vogel, Ph.D., President & CEO, Boehringer Ingelheim Fremont Inc., have joined the CLSA board. CLSA is the nation's largest statewide life sciences public policy advocacy and business solutions organization serving biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers across the state of California.
AGN: 254.32 (-0.54)

Teva (TEVA): Stock Likely to Beat on Earnings in Q2 Again?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:06AM CDT
Our proven model shows that Teva (TEVA) is likely to beat earnings this quarter because it has the right combination of two key ingredients.
AGN: 254.32 (-0.54), RPTP: 5.82 (-0.25), TECH: 112.53 (-1.25), TEVA: 53.19 (-0.42)

RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE
GlobeNewswire - Tue Aug 02, 1:14AM CDT
Recordati and Gedeon Richter today announced the signing of an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic in Western Europe and in Algeria, in Tunisia and in Turkey.
AGN: 254.32 (-0.54)

Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
PR Newswire - Mon Aug 01, 6:00AM CDT
Bioniz Therapeutics, Inc., a biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer, announced today that it has raised $13 million in its Series A funding. The investment syndicate was co-led by Takeda, via its corporate venture arm Takeda Ventures Inc., and Dr. David Pyott, and also includes investments from Mr. Joe Kiani, and Cota Capital. The Company also announced that it has appointed Dr. David Pyott as Chairman of the Board of Directors, effective immediately. Dr. Pyott is the past Chairman and Chief Executive Officer of Allergan Inc. (AGN). In connection with the financing, Ilan Zipkin Ph.D., Senior Investment Director, Takeda Ventures, and Joe Kiani, Chairman and CEO of medical device company Masimo Corporation (MASI), have also joined the Company's Board of Directors.
AGN: 254.32 (-0.54), MASI: 52.57 (-0.36)

Global Anti-aging Market Report 2015-2019 - Analysis, Technologies & Forecasts - Key Vendors: Allergan, Coty, Lumenis - Research and Markets
BusinessWire - Fri Jul 29, 5:46AM CDT
Research and Markets has announced the addition of the "Anti-aging Market: Global Industry Analysis and Opportunity Assessment, 2015-2019" report to their offering.
AGN: 254.32 (-0.54)

Teva expect to close $40.5B Allergan generic deal next week
AP - Wed Jul 27, 3:31PM CDT
NEW YORK (AP) — Israeli drugmaker Teva, the largest generic drug company in the world, said Wednesday it expects to complete its $40.5 billion purchase of the generic drug business of competitor Allergan next week after federal regulators approved the deal.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)

Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition
BusinessWire - Wed Jul 27, 1:36PM CDT
--Added Capabilities, Assets and Talent Advance Teva's Focus on Patient Needs and Providing Affordable Generic Products to Patients at Every Stage of Life Worldwide
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)

After Yesterday's Rally of 1.47% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Jul 27, 11:47AM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $249.00 to a high of $255.48. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $250.75 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 254.32 (-0.54)

Hologic (HOLX) Q3 Earnings: A Surprise in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:31AM CDT
Hologic (HOLX) has a Zacks Rank #2 (Buy) which along with a 0.00 % ESP makes surprise prediction difficult.
AGN: 254.32 (-0.54), LH: 138.58 (-1.05), BMY: 75.13 (-1.06), HOLX: 39.13 (+0.15)

Illumina (ILMN) to Report Q2 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 6:08AM CDT
Illumina (ILMN) has a Zacks Rank #4 (Sell), which along with an ESP of 0.00% makes surprise prediction difficult.
AGN: 254.32 (-0.54), LH: 138.58 (-1.05), ILMN: 165.02 (-5.63), BMY: 75.13 (-1.06)

Edwards Lifesciences (EW) Q2 Earnings: Will It Be a Miss?
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 3:56PM CDT
Edwards (EW) has a Zacks Rank #4 (Sell), which along with a negative ESP of -1.43% makes surprise prediction difficult.
AGN: 254.32 (-0.54), EW: 113.05 (-1.18), LH: 138.58 (-1.05), BMY: 75.13 (-1.06)

Top 7 Research Reports for July 15, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 15, 1:10PM CDT
Top 7 Research Reports for July 15, 2016
AGN: 254.32 (-0.54), DFS: 55.39 (-0.95), XEL: 43.73 (-0.21), BA: 131.59 (-1.62), CL: 74.70 (-0.41), K: 81.71 (-0.66)

Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.32 (-0.54), DPLO: 35.84 (+0.12), HZNP: 19.26 (+0.37), MYL: 46.20 (-0.54)

Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
Arpita Dutt - Zacks Investment Research - Thu Jul 14, 7:10AM CDT
Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
AGN: 254.32 (-0.54), MYL: 46.20 (-0.54), TEVA: 53.19 (-0.42), RDY: 44.19 (-0.31)


Asian shares mixed in cautious trading
By TERESA CEROJANO - AP - Wed Jul 13, 11:01PM CDT
MANILA, Philippines (AP) — Asian shares were mixed Thursday in cautious trading ahead of a Bank of England meeting, Friday's release of China's GDP data, and as investors digest new British Prime Minister Theresa May's Cabinet.
AGN: 254.32 (-0.54)

Michaels and Hess slide, Teva and JetBlue trade higher
AP - Wed Jul 13, 3:27PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Wednesday:
AGN: 254.32 (-0.54), HES: 50.50 (-0.73), JUNO: 30.22 (-0.64), TEVA: 53.19 (-0.42), JBLU: 17.21 (-0.99), AET: 115.91 (+1.46), AIR: 23.72 (-0.28)

Markets Right Now: US stock indexes edge mostly higher
AP - Wed Jul 13, 3:19PM CDT
NEW YORK (AP) — The latest on developments in global financial markets (all times local):
AGN: 254.32 (-0.54)

Why are Allergan (AGN) and Teva Pharma (TEVA) Stocks Up Today?
Madeleine Johnson - Zacks Investment Research - Wed Jul 13, 10:39AM CDT
On Wednesday, shares of Allergan (AGN) and Teva Pharmaceuticals (TEVA) are both on the rise, up around 2% and 3%, respectively, in morning trading after Teva CEO Erez Vigodman said it expects its $40.5 billion acquisition of Allergan's generics business to close any day.
AGN: 254.32 (-0.54), TEVA: 53.19 (-0.42)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 53

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 292

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 26

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 135

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 32

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 69

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 67

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 0

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading

Top 5 Most Recently Viewed Articles

Artprice News Revolutionizes Global Art Market Information

Updated Category News Views 237

Artprice News Launch: A New Chapter in Art Market Reporting Artprice by Artmarket has introduced a groundbreaking initiative with the launch of Artprice News, marking a significant evolution in the landscape of art market information. This innovative news agency is tailored exclusively for the art world, broadcasting valuable insights in 11 languages and spanning 122...

Continue Reading
U-BX Technology Ltd. Responds to Nasdaq Notification on Listing

Updated Category News Views 211

U-BX Technology Ltd. Responds to Nasdaq Notification U-BX Technology Ltd. (NASDAQ: UBXG), recognized as a frontrunner in offering innovative services powered by artificial intelligence to the insurance sector, recently informed stakeholders regarding important notifications received from The Nasdaq Stock Market LLC. Details of Nasdaq Notification Letters On a recent date,...

Continue Reading
Understanding Investor Rights in Newmont Securities Class Action

Updated Category News Views 370

Understanding the Basics of the Newmont Class Action Investors who have sustained losses exceeding $50,000 in Newmont Corporation should take heed of an active class action. This legal effort aims to provide relief for those affected by adverse developments within the company. Faruqi & Faruqi, LLP, a prominent securities law firm, is at the forefront of this investigation...

Continue Reading
Tarte's Record-Breaking Collab: 60 Seconds to Sellout

Updated Category News Views 129

When Makeup Meets Pajamas: The Perfect Storm Picture this: a makeup brand and a lifestyle label dreaming up a collaboration that sends consumers into a full-blown frenzy. In a whirlwind that lasted just 60 seconds, tarte's latest partnership with Roller Rabbit blazed through stock, cementing its place as a record-breaking phenomenon. Maureen Kelly, tarte’s intrepid CEO,...

Continue Reading
What Lessons Can Traditional Investors Learn From the Rise of Ethereum?

Updated Category Crypto Views 3176

Turn the clock back a few decades, and investors on Wall Street would laugh if you tried to pitch the concept of blockchain to them. It’s one of those ideas that sound like they’d technically work but would be impossible to practically execute. Yet today, blockchain and cryptocurrency exist and are proof that the skeptics were wrong. Sadly, many traditional investors...

Continue Reading